Company name:
CareDx Inc
-
IPO SHARE PRICE:$10.00
-
IPO DATE:July 17, 2014
-
TICKER:CDNA
-
MAIN STOCK EXCHANGE:NASDAQ
-
CURRENT HQ LOCATION:1 Tower Place South San Francisco California 94080
-
FISCAL YEAR END:December 31
-
INCORPORATION JURISDICTION:DE
-
ORGANIZED AS THE FOLLOWING LEGAL TYPE:Corporation
-
Investor Relations Webpage:Coming soon!
-
TAX RATE:USA federal corporate nominal income tax rate is 21%
Short Description
CareDx Inc
We are working hard and as soon as possible to provide company description soon. Feel free to reach out to request it sooner: improve@real-clear-investing.com
Income Statement
(USD in thousand)
Selected Quarter:
31-Dec
2020
2020
Revenue
Gross receipts in the form of cash (great!) and promises to pay (Account Receivables - not so great as some of them will never be collected but reality of business!) from all its customers
100%
85.9% —
Testing services revenue
10.1% —
Product revenue
4.0% —
Digital and other revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing services revenue | 21,518 | 25,677 | 28,226 | 29,129 | 31,442 | 36,293 | 45,529 | 50,346 | 163,610 | 201,384 | ||||||||||||||||
| Product revenue | 4,433 | 4,593 | 4,200 | 5,053 | 4,695 | 3,291 | 5,383 | 5,933 | 19,302 | 23,732 | ||||||||||||||||
| Collaboration license and other revenue | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||
| Digital and other revenue | 31 | 1,184 | 1,385 | 1,639 | 2,243 | 2,217 | 2,457 | 2,365 | 9,282 | 9,460 | ||||||||||||||||
| License and other revenue | 31 | - | - | - | - | - | - | - | - | - | ||||||||||||||||
| Total Revenue | $25,982 | $31,454 | $33,811 | $35,821 | $38,380 | $41,801 | $53,369 | $58,644 | $192,194 | $234,576 |
Selected Quarter:
31-Dec
2020
2020
Operating expenses
Cost (labor, materials, depreciation, overhead, etc) for delivering service or manufacturing a product that business sells
105.2%
27.5% —
Sales and marketing
22.8% —
General and administrative
22.7% —
Research and development
22.7% —
Cost of testing services
7.2% —
Cost of product
2.3% —
Cost of digital and other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cost of revenue
|
9,733 | 11,512 | 11,494 | 12,716 | 12,392 | 15,025 | - | - | - | - | ||||||||||||||||
|
Cost of testing services
|
6,838 | - | 7,421 | 7,694 | - | - | 11,900 | 13,301 | 43,932 | 53,204 | ||||||||||||||||
|
Cost of product
|
2,895 | - | 2,986 | 3,758 | - | - | 3,705 | 4,212 | 13,847 | 16,848 | ||||||||||||||||
|
Cost of digital and other
|
- | - | 1,087 | 1,264 | - | - | 1,210 | 1,372 | 5,338 | 5,488 | ||||||||||||||||
|
Gross profit
|
$16,249 | $19,942 | $22,317 | $23,105 | $25,988 | $26,776 | - | - | - | - | ||||||||||||||||
|
Sales and marketing
|
6,925 | 10,644 | 11,058 | 10,267 | 11,723 | 12,134 | 13,870 | 16,131 | 53,858 | 64,524 | ||||||||||||||||
|
Research and development
|
5,614 | 7,630 | 8,521 | 8,946 | 10,013 | 13,129 | 12,474 | 13,325 | 48,941 | 53,300 | ||||||||||||||||
|
General and administrative
|
9,106 | 8,512 | 9,485 | 9,437 | 10,003 | 12,316 | 13,117 | 13,370 | 48,806 | 53,480 | ||||||||||||||||
|
Goodwill impairment
|
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||
|
Change in estimated fair value of contingent consideration
Change in estimated fair value of contingent consideration
|
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||
|
Other expenses
|
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||
|
Total operating expenses
|
$21,645 | $26,786 | $40,558 | $41,366 | $31,739 | $37,579 | $56,276 | $61,711 | $214,722 | $246,844 |
Selected Quarter:
31-Dec
2020
2020
Operating Income
Income after excluding Operating Expenses from Total Revenue
5.2%
5.2% —
Operating Income
Key metric that shows earnings potential of the company's business model
Selected Quarter:
31-Dec
2020
2020
Non-operating expenses
Cost usually unrelated to delivering service or manufacturing a product that business sells
0.4%
0.0% —
CARES Act Provider Relief Fund
0.4% —
Other expense net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in estimated fair value of common stock warrant and derivative liability | (3,009) | (1,351) | 4,346 | 333 | - | - | - | - | (1,495) | - | ||||||||||||||||
| Change in fair value of stock warrants | (3,009) | (1,351) | 4,346 | - | (405) | (664) | 79 | - | - | - | ||||||||||||||||
| CARES Act Provider Relief Fund | - | - | - | - | - | 4,813 | - | - | 4,813 | - | ||||||||||||||||
| Other expense or income | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||
| Other expense net | (74) | (172) | (398) | (75) | (63) | (255) | (254) | (239) | (811) | (956) | ||||||||||||||||
| Early repayment of debt expenses | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||
| Total non-operating income (expense) | (3,083) | (1,523) | 3,948 | 258 | (468) | 3,894 | (175) | (239) | 2,507 | (956) |
Selected Quarter:
31-Dec
2020
2020
Earnings before Interest and Taxes (EBIT)
Income after excluding Operating and Non-operating Expenses from Total Revenue
5.6%
5.6% —
EBIT
Another income metric but unlike Operating Income it is closer to the ultimate income metric - Net Income by removing expenses that are not related to earning Revenue as they are supposed to be accidental and transitory
Selected Quarter:
31-Dec
2020
2020
Interest Expense and Income, Taxes
Expenses driven mostly by company management's choices, nature of business (capital intensive vs not) about financing (debt vs equity) and legal structure
0.3%
0.3% —
Income tax expense or benefit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Interest expense (income)
|
342 | 300 | 37 | 306 | - | - | - | - | 271 | - | ||||||||||||||||
|
Interest expense
|
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||
|
Interest income
|
342 | 300 | 37 | - | 96 | 21 | 29 | - | - | - | ||||||||||||||||
|
Total other expense or income
|
(2,741) | (1,223) | 3,985 | 564 | (372) | 3,915 | (146) | (619) | 2,778 | (2,476) | ||||||||||||||||
|
Income before income taxes
|
(8,137) | (8,067) | (2,762) | (4,981) | (6,123) | (6,888) | (3,053) | (3,686) | (19,750) | (14,744) | ||||||||||||||||
|
Income tax expense or benefit
|
606 | 220 | 949 | 204 | 300 | 330 | 235 | 171 | 1,036 | 684 |
Selected Quarter:
31-Dec
2020
2020
Net income (loss)
Ultimate measure of Income - Net result after excluding all expenses from Total Revenue
6.0%
6.0% —
Net income (loss)
It is a residue that is left from Total Revenue after paying all kind of expenses and belongs to all equity holders in the company. Some of these shareholders such Non-controlling interest or Preferred equity gets their share before Common shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net income (loss)
|
($7,531) | ($7,847) | ($1,813) | ($4,777) | ($5,823) | ($6,558) | ($2,818) | ($3,515) | ($18,714) | ($14,060) | ||||||||||||||||
|
Net income (loss) attributable to non-controlling interests
Net income (loss) attributable to non-controlling interests
|
(25) | - | - | - | - | - | - | - | - | - | ||||||||||||||||
|
Net income (loss) attributable to Company
|
(7,531) | (7,847) | (1,813) | (4,777) | - | - | - | - | (18,714) | - |
Basic Shares Outstanding
Basic shares outstanding as of certain dates reported by Company on its annual and quarterly filings, these numbers are NOT used calculation of basic EPS. They help to see share issuance by company in perspective
Selected Quarter:
31-Dec
2020
2020
EPS
Net Income / Shares Outstanding = EPS before dilution or Basic EPS; Net Income/ ( Shares Outstanding + potentially available shares from conversion of various option instruments)